Skip to main content
. 2022 Oct 20;13:1005045. doi: 10.3389/fimmu.2022.1005045

Figure 1.

Figure 1

Hsp90β-selective inhibitor NDNB1182. (A) Association of high HSP90AB1 expression with worse PSA progression free survival (PFS) and overall survival, with data extracted from the database of a phase 2 clinical trial of ipilimumab in metastatic castration-resistant prostate cancer *P<0.05, log rank test between the two cohorts (47). (B) Association of high HSP90AB1 expression with worse overall survival for anti-PD1 or anti-PD-L1 treatment with data from multiple clinical studies, drawn with KMplot. (C) The generic structure of NDNB1182 and IC50 values against Hsp90 isoforms determined using fluorescence polarization (FP) assay. (D) Western blot of Src in mouse prostate cancer cell line PPS treated with DMSO, NDNB1182 or luminespib for 12 hours, with the semi-quantitative result presented on the right. (E) HPLC result confirming the high purity of NDNB1182. (F) Dose-response curves and IC50 values of NDNB1182 on four cancer cell lines. Nonlinear regression modeling with log(inhibitor) and normalized response of variable slopes was conducted in Graphpad Prism. (G) Dose-response curves and IC50 values of NDNB1182 on primary prostate epithelial cells grown from wild type C57BL/6 mice and the mouse fibroblast cell line L cells. (H) HSP90AB1 transcript levels for prostate-lineage cell lines in the Depmap database portal with the plot generated by Depmap.